{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(12)"],"submitter":["Abu-Amer W"],"funding":["NIH"],"pubmed_abstract":["There are currently no reliable serum biomarkers to aid in the diagnosis of peripheral artery disease (PAD). We hypothesized that circulating fatty acid synthase (cFAS) can be an independent diagnostic biomarker for PAD. Serum cFAS and demographics were compared for patients with and without PAD or chronic limb threatening ischemia (CLTI). Patients with PAD or CLTI had significantly higher serum cFAS content. We observed optimal cutoffs for cFAS in distinguishing between individuals with and without PAD or CLTI. Our study demonstrates that cFAS is an independent serum-based diagnostic biomarker for PAD, can distinguish between patients with PAD vs CLTI, and may predict disease severity."],"journal":["JACC. Basic to translational science"],"pagination":["101411"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12662003"],"repository":["biostudies-literature"],"pubmed_title":["Serum cFAS Content Correlates With Incidence of Peripheral Arterial Disease."],"pmcid":["PMC12662003"],"pubmed_authors":["Meade R","Shorbaji K","Penrose A","Wu SG","Zaghloul MS","Belaygorod L","Alrata L","Semenkovich CF","Arif B","Abu-Amer W","Pyeatte SR","Hafezi S","Zayed MA"],"additional_accession":[]},"is_claimable":false,"name":"Serum cFAS Content Correlates With Incidence of Peripheral Arterial Disease.","description":"There are currently no reliable serum biomarkers to aid in the diagnosis of peripheral artery disease (PAD). We hypothesized that circulating fatty acid synthase (cFAS) can be an independent diagnostic biomarker for PAD. Serum cFAS and demographics were compared for patients with and without PAD or chronic limb threatening ischemia (CLTI). Patients with PAD or CLTI had significantly higher serum cFAS content. We observed optimal cutoffs for cFAS in distinguishing between individuals with and without PAD or CLTI. Our study demonstrates that cFAS is an independent serum-based diagnostic biomarker for PAD, can distinguish between patients with PAD vs CLTI, and may predict disease severity.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-15T04:55:24.215Z","creation":"2026-06-15T03:08:17.528Z"},"accession":"S-EPMC12662003","cross_references":{"pubmed":["41232174"],"doi":["10.1016/j.jacbts.2025.101411"]}}